Abingdon Health Plc (ABDX) - Net Assets
Based on the latest financial reports, Abingdon Health Plc (ABDX) has net assets worth GBX6.30 Million GBX (≈ $766.65 USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (GBX10.55 Million ≈ $1.28K USD) and total liabilities (GBX4.25 Million ≈ $517.35 USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how strategically is Abingdon Health Plc's equity deployed to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | GBX6.30 Million |
| % of Total Assets | 59.71% |
| Annual Growth Rate | N/A |
| 5-Year Change | -75.15% |
| 10-Year Change | N/A |
| Growth Volatility | 248.66 |
Abingdon Health Plc - Net Assets Trend (2016–2025)
This chart illustrates how Abingdon Health Plc's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see ABDX market cap.
Annual Net Assets for Abingdon Health Plc (2016–2025)
The table below shows the annual net assets of Abingdon Health Plc from 2016 to 2025. Also explore ABDX net asset momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | GBX5.30 Million ≈ $644.86 |
+135.66% |
| 2024-06-30 | GBX2.25 Million ≈ $273.64 |
-25.26% |
| 2023-06-30 | GBX3.01 Million ≈ $366.11 |
-53.22% |
| 2022-06-30 | GBX6.43 Million ≈ $782.59 |
-69.84% |
| 2021-06-30 | GBX21.33 Million ≈ $2.59K |
+675.81% |
| 2020-06-30 | GBX2.75 Million ≈ $334.47 |
-54.84% |
| 2019-06-30 | GBX6.09 Million ≈ $740.58 |
+4.71% |
| 2018-06-30 | GBX5.81 Million ≈ $707.29 |
+5126.07% |
| 2016-12-31 | GBX-115.66K ≈ $-14.07 |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Abingdon Health Plc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2187840000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | GBX94.00K | 1.77% |
| Other Comprehensive Income | GBX336.00K | 6.34% |
| Other Components | GBX37.04 Million | 698.92% |
| Total Equity | GBX5.30 Million | 100.00% |
Abingdon Health Plc Competitors by Market Cap
The table below lists competitors of Abingdon Health Plc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Mitra Komunikasi Nusantara Tbk PT
JK:MKNT
|
$322.28K |
|
Sanco Industries Limited
NSE:SANCO
|
$322.53K |
|
Dewhurst plc
LSE:DWHA
|
$323.07K |
|
Ortivus AB ser. A
ST:ORTI-A
|
$325.65K |
|
Desarrolladora Homex S.A.B. de C.V
MX:HOMEX
|
$320.51K |
|
GO.D.M Investments Ltd
TA:GODM
|
$319.94K |
|
Portmeirion Group PLC
LSE:PMP
|
$319.22K |
|
Carclo plc
LSE:CAR
|
$318.91K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Abingdon Health Plc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,249,000 to 5,300,000, a change of 3,051,000 (135.7%).
- Net loss of 3,415,000 reduced equity.
- New share issuances of 5,628,000 increased equity.
- Other comprehensive income increased equity by 167,000.
- Other factors increased equity by 671,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | GBX-3.42 Million | -64.43% |
| Share Issuances | GBX5.63 Million | +106.19% |
| Other Comprehensive Income | GBX167.00K | +3.15% |
| Other Changes | GBX671.00K | +12.66% |
| Total Change | GBX- | 135.66% |
Book Value vs Market Value Analysis
This analysis compares Abingdon Health Plc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 726.40x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 173.37x to 726.40x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-06-30 | GBX0.06 | GBX10.50 | x |
| 2019-06-30 | GBX0.06 | GBX10.50 | x |
| 2020-06-30 | GBX0.03 | GBX10.50 | x |
| 2021-06-30 | GBX0.22 | GBX10.50 | x |
| 2022-06-30 | GBX0.02 | GBX10.50 | x |
| 2023-06-30 | GBX0.01 | GBX10.50 | x |
| 2024-06-30 | GBX0.01 | GBX10.50 | x |
| 2025-06-30 | GBX0.01 | GBX10.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Abingdon Health Plc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -64.43%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -40.51%
- • Asset Turnover: 0.91x
- • Equity Multiplier: 1.76x
- Recent ROE (-64.43%) is above the historical average (-75.92%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 0.00% | -228.89% | 0.16x | 0.00x | GBX-3.17 Million |
| 2018 | 59.68% | 152.95% | 0.33x | 1.19x | GBX2.89 Million |
| 2019 | -20.70% | -55.33% | 0.31x | 1.20x | GBX-1.87 Million |
| 2020 | -122.74% | -64.45% | 0.48x | 3.99x | GBX-3.65 Million |
| 2021 | -32.70% | -60.02% | 0.35x | 1.56x | GBX-9.11 Million |
| 2022 | -330.57% | -749.98% | 0.22x | 1.99x | GBX-21.91 Million |
| 2023 | -115.29% | -85.76% | 0.67x | 2.01x | GBX-3.77 Million |
| 2024 | -56.51% | -20.72% | 1.21x | 2.26x | GBX-1.50 Million |
| 2025 | -64.43% | -40.51% | 0.91x | 1.76x | GBX-3.94 Million |
Industry Comparison
This section compares Abingdon Health Plc's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $338,388,841
- Average return on equity (ROE) among peers: -34.67%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Abingdon Health Plc (ABDX) | GBX6.30 Million | 0.00% | 0.67x | $320.76K |
| ANGLE plc (AGL) | $7.22 Million | 16.76% | 0.27x | $94.18K |
| genedrive plc (GDR) | $8.86 Million | -2.75% | 0.18x | $156.59K |
| Integrated Diagnostics Holdings PLC (IDHC) | $2.31 Billion | 16.16% | 0.34x | $308.10 Million |
| LungLife AI Inc (LLAI) | $13.14 Million | -57.88% | 0.14x | $15.48K |
| Oxford Biodynamics PLC (OBD) | $6.05 Million | -178.79% | 1.66x | $60.04K |
| Proteome Sciences PLC (PRM) | $-270.00K | 0.00% | 0.00x | $63.16K |
| Verici Dx Plc (VRCI) | $19.62 Million | -36.19% | 0.03x | $41.43K |
About Abingdon Health Plc
Abingdon Health Plc develops, manufactures, and distributes diagnostic devices in the United Kingdom, Europe, the United States, Canada, and internationally. It operates through Contract Development, Contract Manufacturing, Product Sales, and Regulatory segments. The company provides a range of professional-use tests and self-tests to various industries, including healthcare, COVID-19, plant heal… Read more